On July 23, Medpace rose 19.2% in after-hours trading, trading at $627.0/share, with turnover of $30.14 million. The surge was driven by the company reporting Q2 results that significantly exceeded Wall Street expectations across all key metrics, accompanied by an upward revision to full-year guidance.

Medpace posted Q2 EPS of $4.25, beating the analyst consensus estimate of $3.97-$3.98 by approximately 7%, representing a 37.1% year-over-year increase from $3.10. Revenue reached $707.3 million, surpassing the $687.6-$689.5 million estimate and up from $603.3 million a year earlier. Net income totaled $121.4 million. New business awards came in at $795.7 million, up 28.2% year-over-year, resulting in a net book-to-bill ratio of 1.13x, signaling continued strong demand. For full-year guidance, the company now expects EPS of $17.25-$17.95 on revenue of $2.81-$2.89 billion, both above consensus estimates of $16.97 and $2.77 billion respectively.

Medpace is a global clinical contract research organization specializing in Phase I-IV clinical development services for the biotechnology, pharmaceutical, and medical device industries, with particular strength in oncology and metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)